CAPECITABINE with concurrent RT

INDICATION (ICD10) C25
1. Locally advanced pancreatic cancer (unlicensed) PS 0, 1, 2

REGIMEN
CAPECITABINE 830mg/m^2 twice daily (1660mg/m^2/day) oral for 5 days per week on days of radiotherapy treatment

CYCLE FREQUENCY AND NUMBER OF CYCLES
For duration of radiotherapy (i.e. 28 days up to 30 days)

ADMINISTRATION
Tablets should be taken 12 hours apart.
Swallowed with water within 30 minutes after a meal, or dissolve in 200ml luke warm water, stir thoroughly (squash may be added if unpalatable).

ANTI-EMETICS
Low risk days 1 to 5 of each week

CONCURRENT MEDICATION REQUIRED

Capecitabine	Mouth and bowel support eg Loperamide, benzydamine mouthwash

EXTRAVASATION AND TYPE OF LINE / FILTERS
Not applicable

INVESTIGATIONS
Blood results required before SACT administration
FBC, U&E and LFTs every cycle
Neutrophils x 10^9/L ≥1.5 (1-1.5 discuss with Consultant)
Platelets x 10^9/L ≥100 (75-100 discuss with Consultant)
Serum creatinine - GFR each cycle
DPYD (dihydropyrimidine dehydrogenase) test
Baseline weight and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

Capecitabine	Palmar plantar (handfoot syndrome) causing red palms and soles – treat with pyridoxine 50mg tds Diarrhoea – treat with loperamide or codeine Cardiotoxicity – monitor cardiac function. To minimise risk of anthracycline induced cardiac failure signs of cardiotoxicity e.g. cardiac arrhythmias, pericardial effusion, tachycardia with fatigue. All patients should be told to report any cardiac symptoms immediately and should be told to stop the medication immediately if any suspicion of cardiac problems. Stomatitis

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS (not exhaustive list check SPC/BNF/Stockleys)

Capecitabine	Brivudine and analogues should be avoided Warfarin Phenytoin Allopurinol

DOSE MODIFICATIONS
DPYD variant identified follow national or local DPD dose modification guidelines.

Haematological
Neutrophils $<1.5 \times 10^9$/l or Platelets $<100 \times 10^9$/l omit
Repeat FBC. If recovered, restart capecitabine, using dose adjustment guidelines below, according to worst grade of haematological toxicity recorded.

Non-haematological
Dose limiting toxicities include diarrhoea, abdominal pain, nausea, stomatitis and handfoot syndrome.
Toxicity can be managed by symptomatic treatment and/or modification of the dose (treatment interruption or dose reduction).
Once the dose has been reduced it should not be increased at a later time.
When capecitabine is stopped for toxicity, the doses are omitted and not delayed.

Toxicity grades	Dose changes within a treatment cycle	Dose adjustment for next cycle/dose (% of starting dose)
Grade 2 - 1st appearance	Interrupt until resolved to grade 0-1	100%
Grade 2 - 2nd appearance	Interrupt until resolved to grade 0-1	75%
Grade 2 - 3rd appearance	Interrupt until resolved to grade 0-1	50%
Grade 2 - 4th appearance	Discontinue treatment permanently	Not applicable
Grade 3 - 1st appearance	Interrupt until resolved to grade 0-1	75%
Grade 3 - 2nd appearance	Interrupt until resolved to grade 0-1	50%
Grade 3 - 3rd appearance	Discontinue treatment permanently	Not applicable
Grade 4 - 1st appearance	Discontinue permanently OR if physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1	50%
Grade 4 - 2nd appearance	Discontinue treatment permanently	Not applicable

Hepatic impairment

Bilirubin of >3xULN or ALT/AST >2.5xULN	Interrupt capecitabine Treatment may be resumed when bilirubin decreases to <3xULN or hepatic aminotransferases decrease to <2.5xULN.

Renal impairment

CrCl (ml/min) >50	give 100% dose
CrCl (ml/min) 30-50	give 75% dose
CrCl (ml/min) <30	contraindicated

REFERENCES
1. SCALOP study